Ardelyx Reports Q1 2026 Earnings and Strategic Growth Initiatives

Ardelyx reported strong year-over-year revenue growth for Ibsrela, driven by its commercial execution strategy. The company is investing in the EXCEL Phase 3 trial to expand into chronic idiopathic constipation (CIC) and reiterated full-year revenue guidance.

By Moby Intelligence Fri, May 1, 2026 at 3:15 AM GMT+3 3 min read · Yahoo Finance · May 1, 2026, 00:15 UTC

Ardelyx Reports Q1 2026 Earnings and Strategic Growth Initiatives

Tickers: $ARDX

Topics: capital allocation earnings pharmaceuticals pipeline development revenue growth

Read the full article at Yahoo Finance

More World news

Global Asset Management Group Signs LOI for $100 Million Affordable Housing Portfolio in Washington, D.C. PR Newswire · November 12, 2026, 17:30 UTC
U.S. Air Conditioner and Heat Pump Shipments Increase 27.3% in September Seeking Alpha · November 12, 2026, 17:27 UTC
Nvidia CEO Jensen Huang Resigns Amid Intelligence Probe Seeking Alpha · November 12, 2026, 17:27 UTC
Oklo and Centrus Energy Sign Multi-Year HALEU Fuel Supply Agreements for Ohio Nuclear Campus Seeking Alpha · November 12, 2026, 17:28 UTC
IRS Announces Increased 401(k) Contribution Limits for 2027 CNBC · November 12, 2026, 17:23 UTC
Bit Digital Announces $865 Million Contract and Commencement of 40MW Billing Seeking Alpha · November 12, 2026, 17:20 UTC
Nvidia CEO Jensen Huang Resigns Amid Investigation and Personal Allegations Motley Fool · November 12, 2026, 17:20 UTC
Argus Research Upgrades Republic Services to Buy Seeking Alpha · November 12, 2026, 17:16 UTC
Moderna Shares Decline Following Analyst Day Projections and Future Cost Concerns Motley Fool · November 12, 2026, 17:13 UTC
United Airlines Restricts AI Agent Access to Booking Systems Due to Cybersecurity and Regulatory Concerns TechCrunch · November 12, 2026, 17:17 UTC